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ABSTRACT  
The Montelukast sodium is a leukotrine receptor antagonist used for the maintenance treatment of asthma, chronic 
asthma attacks and to relieve symptoms of seasonal allergies. The biological half life of montelukast sodium is 2.5 to 
5.5 hrs and poor bioavailability upto 64%. Because of poor bioavailability of montelukast sodium by oral route, there 
is a need to increase its bioavailability by formulating it into buccal dosage forms.  Hence, montelukast sodium is a 
suitable drug for buccal dosage forms and may provide a better therapeutic profile than oral route. In the present 
piece of research work, montelukast sodium buccal films were prepared using different mucoadhesive polymers like 
hydroxy propyl methyl cellulose (5 cps), Eudragit RL-100, poly vinyl pyrrolidone K-30, and different grades of 
carbopol (like carbopol-934, carbopol-940, carbopol-971 P and carbopol-974 P) by solvent casting technique. Buccal 
films were characterized for number of parameters like physical appearance and surface texture, weight uniformity, 
thickness, folding endurance, swelling index, surface pH, in vitro residence time, drug–excipients interaction study, 
drug content uniformity and in vitro drug release study. FT-IR studies revealed that, there was no interaction between 
drug and excipients used. From this study it was concluded that the film containing 5 mg of montelukast sodium were 
prepared by using eudragit RL 100 with hydroxy propyl methyl cellulose, hydroxy propyl methyl cellulose with 
carbopol 934, and  hydroxy propyl  methyl cellulose with carbopol 940 (F3,  F4, and  F5  formulations) were  best 
formulations. Hence these formulations of montelukast sodium  mucoadhesive buccal films promising one as the 
controlled drug delivery, shows moderate swelling, convenient resident time will lead to improve the bioavailability 
and greater therapeutic efficacy. 
KEYWORDS: Montelukast sodium, eudragit RL-100, hydroxy propyl  methyl cellulose, poly  vinyl pyrrolidone, 
buccal film, in-vitro release. 
 
*Address for Correspondence 
Dr. N. G. Raghavendra Rao, Professor, and HOD, P.G Department of Pharmaceutics, Luqman College of Pharmacy, 
Old Jewargi Road, Gulbarga-585102, Karnataka. E-mail: ngraghu@rediffmail.com 
 
INTRODUCTION 
The interest in novel rout of drugs administration occurs 
from their ability to enhance the  bioavailability of the 
drugs  impaired  by  narrow  absorption  windows  in  the 
gastrointestinal  tracts.  Drugs  delivery  via  the  buccal 
routs using bioadhesive dosage forms offer such a novel 
routs of drugs administration. This route has been used 
successfully  for  the  systematic  delivery  of  number  of 
drugs  candidates
1-5.  Problems  such  as  high  first  pass 
metabolisms  and  drugs  degradation  in  the 
gastrointestinal  tract  can  be  circumvented  by 
administrating  the  drug  buccal  routes
6,7.  Moreover, 
buccal  drug  delivery  offers  safe  and  easy  method  of 
drugs  utilization,  because  drug  absorption  can  be 
promptly  terminated  in  case  of  toxicity  by  removing 
buccal dosage form from buccal cavity. 
Substantial  efforts  have  recently  been  focused  upon 
placing a drug or drug delivery  system  in  a particular 
region of the body for extended period of time. This need 
is  not  only  for  local  targeting  of  drugs  but  also  for  a 
better control of systemic drug delivery
8. Mucoadhesive 
drug delivery systems are delivery systems, which utilize 
the property of bioadhesion of certain polymers, which 
become adhesive on hydration and hence can be used for 
targeting of drug to particular region of the body
9. 
The  montelukast sodium (MS)  is a  leukotrine receptor 
antagonist (LTRA) used for the maintenance treatment of 
asthma, chronic asthma attacks and to relive symptoms 
of  seasonal  allergies
10.  The  main  drawback  of NG Raghavendra Rao et al / IJRAP 2011, 2 (2) 491-497 
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conventional MS formulation is that it undergoes hepatic 
first  pass  metabolism.  Thus,  it  shows  plasma  or 
biological  half-life 2.5 to 5.5 hrs
11, thereby  decreasing 
bioavailability up to 64% 
12. The present work describes 
such delivery system, which will improve the biological 
half-life as well as bioavailability of MS. In the present 
research  work,  MS  buccal  films  were  prepared  using 
different  mucoadhesive  polymers  like  hydroxy  propyl 
methyl cellulose (HPMC) (5 cps), Eudragit RL-100, poly 
vinyl  pyrrolidone  (PVP)  K-30,  and  different  grades  of 
carbopol  (CP-934,  940,  971  P,  and  974  P)  by  solvent 
casting  technique.  The  prepared  buccal  films  were 
characterized for different parameters. 
 
MATERIALS AND METHODS 
MS was obtained as gift sample from Morepen Pharma. 
Pvt. Ltd., Solan (Delhi). Eudragit RL-100 was obtained 
as gift sample form Evonik Pharma Pvt. Ltd., Mumbai. 
Carbopol  971  P  (CP  971P)  and  carbopol  974  P  (CP 
974P)  were obtained  as  gift  sample  from  AstraZeneca 
Pharma India Ltd, Bangalore. HPMC (5 cps), propylene 
glycol (PG), and PVP K-30 were purchased from S.D. 
Fine  Chem.  Ltd.,  Mumbai  and  Himedia  Chem.  Lab., 
Mumbai  respectively.  Carbopol  934  (CP  934)  and 
carbopol 940 (CP 940) were purchased from S.D. Fine 
Chem. Ltd., Mumbai.  
Preparation of the films 
Buccal  films  of  MS  were  prepared  by  solvent  casting 
technique  employing  mercury  as  substrate 
13. 
Compositions  of  circular  cast  films  of  various 
formulations  are  mentioned  in  Table  1.  The 
mucoadhesive films were prepared using polymers like 
HPMC (5 cps), different grades of CP, Eudragit RL-1OO 
and  PVP  K-30.  PG  was  used  as  plasticizer.  The 
calculated  amount  of  polymer  was  dispersed  in  three 
fourth  volume  of  water  with  continuous  stirring  using 
magnetic stirrer and the final volume was adjusted with 
distilled  water.  In  case  of  Eudragit  RL-100  containing 
films, a polymer was firstly dissolved in ethanol (95%) 
with continuous stirring
14. The calculated amount of MS 
was  incorporated  in  the  polymeric  solutions  after 
levigation  with  0.1ml  of  PG.  The  solution  was  casted 
onto mercury substrate then kept in hot air oven at 40
0 
for 24 h. All the films were dried and cut into size 10 
mm, each film containing 5 mg of MS and were packed 
in aluminum  foil. The 10  mm  MS  films are shown  in 
Fig1.  
Evaluation of Mucoadhesive Buccal films 
The prepared buccal films were evaluated for different 
properties:  Physical  properties  like  weight  uniformity, 
thickness, folding endurance, swelling index, surface pH, 
and  mechanical  properties  like  in-vitro  residence  time, 
bursting  strength  of  films  and  evaluation  of  MS  films 
like  drug  content,  in-vitro  release  study  and  FTIR 
studies. 
Appearance of the film was evaluated by observing the 
color,  elegance,  stickiness  and  texture.  Weight 
uniformity  of  the  10  mm  film  was  measured  using 
electronic  balance.  Three  films  of  the  size  10  mm 
diameter  were  weighed  individually  and  the  average 
weights were calculated
15,16. The thickness of each film 
was measured using screw gauge with a least count of 
0.01 mm at different spots of the films. The thickness 
was  measured at three different spots of the  films and 
average  was  taken
16,17.  The  weight  uniformity  and 
thickness  of  all  formulations  was  recorded  (n=3).  The 
flexibility  of  films  can  be  measured  quantitatively  in 
terms  of  folding  endurance.  Folding  endurance  of  the 
films was determined by repeatedly folding a small strip 
of the films (approximately two cm
2) at the same place 
until it broke. The number of times films could be folded 
at the same place, without breaking gives the value of 
folding endurance
18. The folding endurance and percent 
swelling index of films are carried out for three times. 
Weight  and  area  increase  due  to  swelling  were 
measured
19,20. 
Weight increase due to swelling: A drug-loaded patch of 
two cm
2 was weighed on a preweighed cover slip. It was 
kept in a petridish and 50 ml of water was added. After 
every  5  min,  the  cover  slip  was  removed,  wiped  with 
tissue paper, and weighed upto 30 min. The difference in 
the weights gives the weight increase due to absorption 
of water and swelling of patch.  
Area increase due to swelling: A drug loaded patch size 
of two cm
2 was cut and placed in a petridish. A graph 
paper was placed beneath the petridish, to measure the 
increase in the area. After determination of the original 
film weight, the samples were allowed to swell on the 
surface of agar plate kept in a hot air oven maintained at 
37
 0. An increase in the length and breadth of the patch 
was noted at five min intervals for 60 min and the area 
was  calculated.  The  percent  swelling,  %  S,  was 
calculated using the following equation: 
  % S   =  100
Xo
Xo   - Xt
x  
  Where,  Xt  is  the  weight  or  area  of  the  swollen 
patch after time t and X 0 is the original patch weight or 
area at zero time. 
Surface pH was measured by placing three films of each 
formulation were allowed in contact with 1ml of distilled 
water. The surface pH was noted by bringing a combined 
glass electrode or pH paper near the surface of films and 
allowing equilibrate for 1 min
21. A mean of three reading 
was  recorded  (n=3).  In-vitro  residence  time
22  was NG Raghavendra Rao et al / IJRAP 2011, 2 (2) 491-497 
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determined  using  USP  disintegration  apparatus.  The 
disintegration medium was 800ml of 0.5% SLS solution 
maintained  at  37  ±  2
0.  The  segments  of  rat  intestinal 
mucosa, each of   three cm  length, were glued to the 
surface  of  a  glass  slab,  which  was  then  vertically 
attached to the apparatus. Three mucoadhesive films of 
each  formulation  were  hydrated  on  one  surface  using 
0.5% SLS solution and the hydrated surface was brought 
into contact with the mucosal membrane. The glass slab 
was  vertically  fixed  to  the  apparatus  and  allowed  to 
move up and down. The film was completely immersed 
in the 0.5% SLS solution at the lowest point and was out 
at  the  highest  point.  The  time  required  for  complete 
erosion  or  detachment  of  the  films  from  the  mucosal 
surface  was  recorded  (n=3).  A  test  for  measuring  the 
resistance of films to bursting and reported in kilo-Pascal 
or pounds per square inch or Kg/cm
2. The burst strength 
of all the films was evaluated by using standard bursting 
strength tester (Fig 2). The  films were tested for drug 
content  uniformity  by  UV-Spectrophotometric  method. 
Films of 10 mm diameter were cut from three different 
places from the casted films
23. Each film was placed in 
100  ml  volumetric  flask  and  dissolved  in  0.5%  SLS 
solution and 5 ml is taken and diluted with 0.5% SLS 
solution up to 10 ml. The absorbance of the solution was 
measured at 342 nm using UV/visible spectrophotometer 
(Shimadzu UV-1700). The percentage drug content was 
determined  using  the  standard  graph  and  the  same 
procedure  was  repeated  for  three  films  (n=3).  In-vitro 
release  studies  were  carried  out  by  attaching  sigma 
dialysis  membrane  to  one  end  of  the  open  cylinder, 
which acts as donor compartment. The prepared buccal 
films  containing  drug  was  placed  inside  donor 
compartment,  which  is,  agitated  continuously  using 
magnetic stirrer and then temperature was maintained at 
37 ± 1
0 
24. Receptor compartment consists of 100 ml of 
0.5 % SLS solution, sample of 2 ml were withdrawn at 
periodic  intervals  from  receptor  compartment  and 
replaced  with  fresh  2  ml  of  0.5  %  SLS  solution 
immediately  and  the  drug  release  was  analyzed 
spectrophotometrically  at  342  nm.  Release  rate  was 
studied for all designed formulations.  
 
RESULT AND DISCUSSION 
Mucoadhesive  films  of  MS  were  prepared  using 
mucoadhesive polymers HPMC (5 cps), different grades 
of CP, PVP K-30 and Eudragit RL-100. PG was used as 
the plasticizer and as well as penetration enhancer. All 
the films were shows smooth surface and elegant texture. 
The  films  were  characterized  for  their  physical 
characteristics, surface pH, thickness, folding endurance, 
drug  content  uniformity,  percent  swelling  index  and 
release  characteristics  are  given  in  Table  2.  The  film 
weights of 10 mm film was found to be in the range of 
32.33 ± 1.152 to 37.66 ± 0.576 mg and film thickness 
was observed to be in the range of 0.253 ± 0.016 to 0.353 
± 0.020 mm.  
Considering the fact that acidic or alkaline pH may cause 
irritation to the buccal mucosa and influence the degree 
of  hydration of polymer, the surface pH of the  buccal 
films was determined to optimize both drug permeation 
and  mucoadhesion.  Attempts  were  made  to  keep  the 
surface pH as close to buccal / salivary pH as possible, 
by the proper selection of the polymer for developing the 
buccal films. The surface pH of all the films was within 
the range of salivary pH. No significant difference was 
found in surface pH of different films. 
The  folding  endurance  was  measured  manually,  by 
folding the film repeatedly at a point till they broke. The 
breaking  time  was  found  to  be  highest  for  F7  (286  ± 
3.464) and lowest for F3 (260 ± 1.000). It was found that 
folding endurance of HPMC films was increased by the 
addition of polymers in the order; PVP K-30, CP-940, 
CP-934, CP-971P, CP-974P and decreased by addition of 
Eudragit RL-100. The  folding endurance  values of the 
films were found to be optimum and therefore the films 
exhibited good physical and mechanical properties. Fig 3 
shows  the  results  of  percent  swelling  index.  The 
comparative  percentage  swelling  behaviors  for  various 
formulations  were  given  in  Table2.  The  percentage 
swelling of HPMC (5 cps) films was reduced by addition 
of different grades of carbopol and eudragit RL-100 and 
increased by the addition of PVP K-30. The PVP K-30 
containing films showed higher percent swelling due to 
freely  soluble  in  water.  The  water-soluble  hydrophilic 
additive dissolves rapidly resulting in high porosity. The 
incorporation of PVP K-30 induced significant reduction 
of in-vitro residence time of the studied formulae, which 
may correlate with the increase in swelling behavior due 
to enhanced erosion rate. The in-vitro residence time was 
determined using USP disintegration apparatus. In-vitro 
residence time of the  film was  in the range of  3.13 ± 
0.151 to 5.43 ± 0.057 hrs. The in-vitro residence time of 
the  mucoadhesive  polymers  are  observed  as  given  in 
Table 2. The drug content in formulations was uniform 
with the range of 94.33 ± 1.175 to 96.33 ± 1.001 %. On 
the basis determination, it was considered that the drug 
was  dispersed  uniformly  through  out  the  film.  The 
bursting strength of films is in the range of 4.366 ± 0.267 
to  5.93  ±  0.057  Kg/cm
2.  The  percentage  drug  content 
uniformity  and  bursting  strength  results  of  all 
formulations are given in Table 2. The in-vitro release 
studies of various formulations were performed in 0.5% 
SLS solution at 342 nm. Distinguishable difference was NG Raghavendra Rao et al / IJRAP 2011, 2 (2) 491-497 
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observed  in  the  release  pattern  of  MS  film  containing 
different grades of CP, PVP K-30 and Eudragit RL-100 
in  graph  plotted  between  the  cumulative  percent  drug 
released from the formulation and time (Fig 4). During 
diffusion, PVP K-30 containing films swelled forming a 
gel  layer  on  the  exposed  film  surfaces.  The  loosely 
bound  polymer  molecules  in  these  films  were  readily 
eroded, allowed the easy release of MS as compared to 
different grades of CP and Eudragit RL-100. After 8 h 
the release was found in the range of 74.24 - 93.62 % in 
all formulations.   
Kinetics  drug  release  results  were  given  Table  3  and 
shown in Figs 4-5, correlation coefficient (r
2) values are 
significantly  correlation  (99%  probability  level)  was 
found and also coefficient (r
2) values are higher than that 
of first-order release kinetics. It may be concluded that 
release kinetics followed zero order. Mechanism of drug 
release pattern i.e. diffusion and swelling was confirmed 
by  Higuchi  plots.  (Fig  6)  shows  the  graphical 
representation  of  cumulative  percentage  drug  release 
versus square root of time. The Higuchi plots were found 
to  be  linear  with  correlation  coefficient  values  were 
given in Table 3. It was concluded that the release of 
drug  from  the  films  followed  the  diffusion-controlled 
mechanism  in  all  the  formulations.  The  plots  of  log 
cumulative percentage drug release versus log time were 
found to be linear to the all formulations. From Fig 7, it 
is  concluded  that  the  release  of  MS  from  films  have 
obeyed  Super  Case-  II  transport.  The  correlation 
coefficient values of Peppas plot were given in Table 3.  
The IR (Fig 8) spectrum of pure drug MS exhibited has a 
broad band around 3411 cm
-1 indicating overlapping of 
these  peaks.  The  peaks  due  to  the  C-H  peaks  have 
appeared as shoulders between 2900 cm
-1 to 3100 cm
-1. 
The C=O peak has appeared at 1636 cm
-1  along with a 
merged peak at 1613 cm
-1. This is due to the complex 
structure  of  the  drug  molecule.  In  formulation  F3  is 
supervised to notice that in this case no change has been 
observed  in  IR  spectra.  Suggesting  that  characteristic 
absorption  peaks  are  remained  unaffected  in  the  F3 
formulation. The formulation F4 was prepared by using 
CP 934, HPMC and drug. In this case viscosity of CP is 
in the range of 29000 to 39000. To know exactly what 
the nature of formulation spectral measurement is carried 
out. The present of distinct carbonyl peak around 1620 
cm
-1  indicating  that  carbonyl  group  of  drug  has 
remaining  intact  and  also  distinct  OH  peak  has  been 
observed  at  3400  cm
-1  which  may  be  due  to  the  OH 
group  of  drug  molecule.  These  data  along  with  the 
aromatic  C-H peak observed at 2900 cm
-1. Suggesting 
that  drug  has  remained  intact  without  undergoing  any 
chemical change. However weak absorption peak of OH 
may  be  due  to  the  drug  has  undergone  hydrogenic 
bonding  with  excipients.  Hence  this  is  not  a  chemical 
product  simple  formulation.  In  formulation  F5  shows 
same absorption peaks a little change in the nature of IR 
spectrum of resulting  formulation  has  no effect during 
the  formulation.  The  formulated  product  obtained 
exhibited IR spectrum almost at the same range. 
 
CONCLUSION 
From this study it was concluded that the film containing 
5 mg of MS were prepared by using eudragit RL 100 
with HPMC, HPMC with CP 934, and HPMC with CP 
940  (F3,  F4,  and  F5  formulations)  were  best 
formulations.  Hence  these  formulations  of  MS 
mucoadhesive buccal films showing promising results as 
the  controlled  drug  delivery,  moderate  swelling, 
convenient resident time, will lead to greater therapeutic 
efficacy, and improve the bioavailability. 
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Table 1: Composition of different Mucoadhesive buccal films of MS 
 
 
Ingredients 
Formulation code 
F1  F2  F3  F4  F5  F6  F7 
MS (mg)  31  31  31  31  31  31  31 
HPMC (mg)  960  960  960  960  960  960  960 
PVP-K30 (mg)  ---  60  ---  ---  ---  ---  --- 
Eu RL-100 (mg)  ---  ---  60  ---  ---  ---  --- 
CP-934 (mg)  ---  ---  ---  60  ---  ---  --- 
Ethanol (95%) (ml)  ---  ---  04  ---  ---  ---  --- 
Propylene glycol (ml)  0.1  0.1  0.1  0.1  0.1  0.1  0.1 
 
Each 10 mm film contains 5 mg of MS, HPMC - Hydroxy propyl methyl cellulose (5cps), PVP K-30- Poly vinyl pyrrolidone K-30,  Eu RL-100 - Eudragit RL-1OO, and 
Carbopol 
 
 
Table 2: Physical evaluation of Mucoadhesive buccal films of MS 
 
FC 
 
Weight 
(mg) 
 
 
Thickness 
(mm) 
 
 
Surface pH 
 
 
 
Folding 
endurance 
 
 
% Swelling 
index 
 
 
in-vitro 
residence 
time(h) 
 
% Drug 
content 
 
 
Bursting 
strength 
 
 
F1 
34.66 ± 
1.526 
0.253 ± 
0.016  6.83 ± 0.057  266 ± 2.000  36.43 ± 2.426  3.40 ± 0.100  94.66 ± 
1.545  5.233 ± 0.251 
F2 
37.33 ± 
1.154 
0.263 ± 
0.005  6.76 ± 0.152  277 ± 3.460  43.48 ± 0.606  3.13 ± 0.151  94.33 ± 
1.175  5.033 ± 0.378 
F3 
37.66 ± 
0.576 
0.253 ± 
0.016  6.06 ± 0.152  260 ± 1.000  31.63 ± 3.095  5.43 ± 0.057  96.33 ± 
1.001  4.366 ± 0.267 
F4 
33.66 ± 
1.152 
0.343 ± 
0.011  6.56 ± 0.057  281 ± 3.605  33.57 ± 1.484  4.27 ± 0.025 
95.05 ± 
0.355  5.73 ± 0.057 
F5 
32.33 ± 
1.152 
0.353 ± 
0.020  6.30 ± 0.100  280 ± 2.645  32.93 ± 1.345  5.06 ± 0.110  95.23 ± 
0.880  5.93 ±  0.057 
F6 
34.33 ± 
1.527 
0.323 ± 
0.015  6.46 ± 0.057  282 ± 3.000  36.21 ± 1.637  3.58 ± 0.102  95.17 ± 
2.403  5.46 ± 0.152 
F7 
35.00 ± 
2.000 
0.346 ± 
0.005  6.46 ± 0.152  286 ± 3.464  35.12 ± 1.739  4.15 ± 0.100  95.99 ± 
2.646  5.66 ± 0.251 
 
Formulation code: FC 
Note: Values in parenthesis are standard deviation (±SD) 
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Table 3: Kinetic parameters of MS buccal films 
 
Formulation 
code 
Zero-
order 
(r
2) 
First- 
order 
(r
2) 
Highuchi 
plot (r
2) 
Peppas 
plot (r
2) 
F1  0.9755  0.8143  0.9053  0.9638 
F2  0.9909  0.8271  0.9426  0.9853 
F3  0.9674  0.8707  0.9095  0.9863 
F4  0.9913  0.9283  0.9439  0.9875 
F5  0.9896  0.9226  0.9398  0.9889 
F6  0.9952  0.9311  0.9538  0.9905 
F7  0.9942  0.9343  0.9501  0.9894 
 
Note: All the values are mean of three observation 
 
 
Fig 1: 10 mm buccal films containing MS 
 
 
Fig 2: Bursting strength tester 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3: percentage-swelling index of different MS film formulations 
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Fig 4: Comparative in-vitro drug release profiles of formulations F1 to F7. 
In-vitro drug release was determined in 0.5% SLS solution  from formulations F-1 
(-□-), F-2 
(-■-), F-3 (-▲-), F-4 (-×-), F-5 (-○-), F-6 (-●-), and F-7 (..-..) . 
 
0
20
40
60
80
100
120
0 2 4 6 8 10
Time (h)
L
o
g
 
C
u
m
.
 
%
 
D
r
u
g
 
R
e
m
a
i
n
i
n
g
 
 
Fig 5: Log cumulative drug remaining of different formulations. F-1 (-□-), F-2 (-
■-), F-3 (-▲-), 
F-4 (-×-), F-5 (-○-), F-6 (-●-), and F-7 (..-..) . 
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Fig 6: Higuchi plot of different formulations F-1 (-□-), F-2 (-■-), F-3 (-▲-), F-4 (-
×-), F-5 (-○-), 
F-6 (-●-), and F-7 (..-..) . 
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Fig 7: Peppas plot of different formulations F-1 (-□-), F-2 (-■-), F-3  
(-▲-), F-4 (-×-), F-5 (-○-), F-6 
(-●-), and F-7 (..-..) . 
 
 
 
 
Fig 8: A- FTIR spectra of pure drug MS, B- FTIR spectra of formulation F3, 
 C- FTIR spectra of formulation F4, and D- FTIR spectra of formulation F5. 
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